Adipocyte Enhancer Binding Protein 1 (AEBP1) Inhibition as a Potential Anti-Fibrotic Therapy in Heart Failure

Area of Science:

• Cardiovascular Biology
• Fibrosis Research
• Molecular Medicine

Background:

• Persistent fibroblast activation leads to myocardial fibrosis and heart failure (HF).
• Adipocyte enhancer binding protein 1 (AEBP1) is implicated in fibrosis but its role in the heart is unclear.
• Elevated AEBP1 expression correlates with human HF.

Purpose of the Study:

• To define the role of AEBP1 in myocardial fibrosis and cardiac remodeling.
• To investigate AEBP1 as a therapeutic target for heart failure.

Main Methods:

• Fibroblast-specific knockout and cardiac-specific knockdown of AEBP1 in murine models.
• Myocardial ischemia and pressure-overload injury models.
• Ex vivo human myocardial tissue culture studies.
• Analysis of pro-fibrotic transcription factors and genes.

Main Results:

• AEBP1 knockout/knockdown significantly improved cardiac function and prevented pathological remodeling in mice.
• ACLP overexpression induced pathological remodeling in human hearts; AEBP1 knockdown induced reverse remodeling.
• AEBP1 regulates key pro-fibrotic genes (e.g., MRTFB, RUNX2, COL1A1).

Conclusions:

• AEBP1 is a critical mediator of myocardial fibrosis and adverse cardiac remodeling.
• AEBP1 inhibition is a promising therapeutic strategy for acute and chronic heart failure.